Publications by authors named "A Pink"
Importance: Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults with moderate to severe PN in a previous 16-week phase 3 study (OLYMPIA 2).
Objective: To assess the efficacy and occurrence of adverse events in adults with moderate to severe PN treated with nemolizumab vs those receiving placebo.
Background: More patients with moderate-to-severe plaque psoriasis achieved responses with JNJ-77242113, a targeted oral peptide inhibiting interleukin (IL)-23 receptor signaling, versus placebo at Week(W)16 of the phase 2 FRONTIER-1 study.
Objective: FRONTIER-2, a long-term extension of FRONTIER-1, evaluated JNJ-77242113 through 1 year.
Methods: FRONTIER-1 participants received JNJ-77242113 at doses from 25mg once daily (QD) to 100mg twice daily (BID) or placebo, through W16.
Subjective status is the evaluation of one's social or socioeconomic status relative to others. Lower subjective status has been associated with risk of overweight/obesity, poorer metabolic health, and obesogenic food preferences and eating behaviors. However, these findings are predominantly based on studies of adolescents and young adults.
View Article and Find Full Text PDFArticle Synopsis
- Atopic dermatitis (AD) is a prevalent skin condition that can occur in individuals of any age, and while dupilumab shows promising efficacy as a monoclonal antibody therapy, its use has been linked to a higher occurrence of ocular side effects.
- The British Association of Dermatologists and the Royal College of Ophthalmologists developed guidance on how to manage these dupilumab-related ocular surface disorders (DROSD) after forming a multidisciplinary group to review literature and recommendations.
- Key recommendations include that treatment with dupilumab should not be delayed for most eye issues, hydration drops are not advised as preventive measures, and specific guidance is provided for managing DROSD in both children under 7 and those older, with a focus on
Article Synopsis
- * The trials involved adult and adolescent participants with moderate-to-severe atopic dermatitis and were conducted across 22 countries, comparing the effects of 30 mg of nemolizumab versus a placebo alongside topical corticosteroids.
- * Key measures included improvements in skin clear-up (IGA score) and eczema severity (EASI-75), as well as pruritus and sleep disturbances at various intervals, with outcomes assessed through masked evaluators.